A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. 1996

P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center, Lee Hospital, Johnstown, PA, USA.

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010742 Phospholipid Ethers Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues. Ether Phosphatidates,Ether Phospholipids,Glycerol Phosphate Ethers,Glycerophosphate Ethers,1-Alkyl-2-Acylphosphatidates,1 Alkyl 2 Acylphosphatidates,Ethers, Glycerol Phosphate,Ethers, Glycerophosphate,Ethers, Phospholipid,Phosphate Ethers, Glycerol,Phosphatidates, Ether,Phospholipids, Ether
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
December 1984, American journal of clinical oncology,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
November 1992, Investigational new drugs,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
November 1983, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
December 1986, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
October 1983, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
November 1991, Investigational new drugs,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
January 1982, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
January 1982, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
September 1983, Cancer treatment reports,
P V Woolley, and C J Schultz, and G I Rodriguez, and R A Gams, and K W Rowe, and M L Dadey, and D D Von Hoff, and J J McPhillips
February 1982, American journal of clinical oncology,
Copied contents to your clipboard!